Melanoma & Skin Cancer | Specialty

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

February 24th 2021

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Dr. Davies on Selecting Between Combination Regimens in BRAF-Mutant Melanoma

February 17th 2021

Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

February 17th 2021

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 9th 2021

February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Dr. Sullivan on Future of Triplet Therapies in Melanoma

February 9th 2021

Ryan Sullivan, MD, discusses the future of triplet therapies for patients with melanoma.

Future Directions in Metastatic Melanoma

February 5th 2021

Dr. Kudchadkar on Future Research Directions for Rare, Non-Melanoma Skin Cancers

February 2nd 2021

Ragini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.

Looking at Approved Agents in Metastatic Melanoma

January 29th 2021

Metastatic Melanoma Treatment Decisions

January 29th 2021

Toripalimab Granted FDA Fast Track Status for Mucosal Melanoma

January 25th 2021

January 25, 2021 - The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.

Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma

January 22nd 2021

Reinhard Dummer, MD, shares his approach for selecting between targeted approaches and immunotherapy agents in the adjuvant treatment of patients with melanoma.

Molecular Testing in Metastatic Melanoma

January 22nd 2021

The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

January 22nd 2021

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Treatment Goals and Patient Decisions in Melanoma

January 15th 2021

A Look at the KEYNOTE-054 and COMBI-AD Data

January 15th 2021

Dr. Sullivan on Sequencing Targeted Therapy and Immunotherapy in Melanoma

January 13th 2021

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

FDA Grants Fast Track Status to Cavrotolimod for Merkel Cell Carcinoma, CSCC

January 11th 2021

January 11, 2021 - The FDA has granted fast track designations to cavrotolimod for use in combination with a PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma that is refractory to previous PD-1 blockade and for use in combination with a PD-1/PD-L1 agent in those with advanced or metastatic cutaneous squamous cell carcinoma that is refractory to previous PD-1/PD-L1 blockade.